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Abstract
Introduction: Patients presenting with painless hematuria form a large part of the urological patient population. In
many cases, especially in younger patients, the cause of hematuria is harmless. Nonetheless, hematuria could be a
symptom of malignant disease and hence most patients will be subject to cystoscopy. In this study, we aimed to
develop a prediction model based on methylation markers in combination with clinical variables, in order to stratify
patients with high risk for bladder cancer.
Material and Methods: Patients (n=169) presenting with painless hematuria were included. 54 patients were
diagnosed with bladder cancer. In the remaining 115 patients, the cause of hematuria was non-malignant. Urine
samples were collected prior to cystoscopy. Urine DNA was analyzed for methylation of OSR1, SIM2, OTX1, MEIS1
and ONECUT2. Methylation percentages were calculated and were combined with clinical variables into a logistic
regression model.
Results: Logistic regression analysis based on the five methylation markers, age, gender and type of hematuria
resulted in an area under the curve (AUC) of 0.88 and an optimism corrected AUC of 0.84 after internal validation by
bootstrapping. Using a cut-off value of 0.307 allowed stratification of patients in a low-risk and high-risk group,
resulting in a sensitivity of 82% (44/54) and a specificity of 82% (94/115). Most aggressive tumors were found in
patients in the high-risk group. The addition of cytology to the prediction model, improved the AUC from 0.88 to 0.89,
with a sensitivity and specificity of 85% (39/46) and 87% (80/92), retrospectively.
Conclusions: This newly developed prediction model could be a helpful tool in risk stratification of patients
presenting with painless hematuria. Accurate risk prediction might result in less extensive examination of low risk
patients and thereby, reducing patient burden and costs. Further validation in a large prospective patient cohort is
necessary to prove the true clinical value of this model.
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Introduction
Hematuria is one of the most common symptoms in
urological practice, as up to 20% of all urological visits are for
hematuria [1]. Hematuria in the adult population can have
different causes, e.g. urinary tract infections, urolithiasis,
benign prostate enlargement (BPH), and urologic
malignancies. A urological cancer is found in approximately 5%
of patients presenting with microscopic hematuria and in
around 20% of patients with macroscopic hematuria [2,3].
However, in up to 60% of the patients no source of bleeding is
found. Thus, most important in the evaluation of hematuria is
the discrimination between a malignant and non-malignant
cause. As a consequence, patients will be subject to an
extensive examination, including cystoscopy, cytology and
imaging of the upper urinary tract. The sensitivity of cystoscopy
for the detection of bladder cancer (BC) is high, ranging from
68-83% [4,5]. Yet, it is an invasive procedure, causing pain and
discomfort. Cytology has a high specificity, but a poor
sensitivity especially for the detection of low-grade BC.
Therefore cytology is only used in combination with
cystoscopy.
The use of molecular markers in the assessment of
hematuria could be of importance in order to reduce costs and
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to avoid invasive diagnostic procedures. However, none of the
current investigated markers have a high enough sensitivity
and specificity to accurately distinguish between malignant and
non-malignant causes.
Recently, we developed a combination of methylation
markers for urine-based follow-up of bladder cancer patients.
The sensitivity of the combination of markers was 74% for the
detection of bladder cancer recurrences [6]. The aim of the
current study is to investigate whether these markers could
also be used to predict the risk of urothelial cell carcinoma
(UCC) in patients presenting with painless microscopic and
macroscopic hematuria.
Material and Methods
Patients and urine samples
In this study, urine samples were included from patients
presenting with painless microscopic or macroscopic
hematuria. All urine samples were retrieved from a sample
bank. This sample bank contained urine samples that were
prospectively collected prior to cystoscopy between January
2007 and July 2012 at the Urology outpatient departments of
Erasmus MC, Rotterdam and Aarhus University Hospital,
Denmark. There were 54 urine samples available from which
the cause of hematuria was malignant. As control group we
included 115 hematuria samples with a non-malignant cause.
All patients were examined by cystoscopy, computer
tomography of the abdomen, and renal ultrasound. In addition,
urine cytology was performed. Bladder tumors were biopsied
and confirmed by histology. Urine samples were collected prior
cystoscopy and were processed within 12-hours after
collection. Urine samples were centrifuged for 10 minutes at
2000*g. Cell pellets were re-suspended in 1ml PBS and
centrifuged for minutes at 3000*g. Supernatant was discarded
and cell pellets were stored at -80°C until DNA isolation. DNA
was extracted using the QIAamp mini and Blood kit (Qiagen)
according to manufacturer’s protocol. Samples from Erasmus
MC were used according to the code of secondary use of
human tissue (www.federa.org). All patients were checked in
the Erasmus MC opt-out objection system. In case of objection,
patients were excluded from analysis. For minors, parents or
caretakers should have filled in the statement of objection.
Informed written consent was obtained from patients at Aarhus
University Hospital and the study was approved by The Central
Denmark Region Committees on Biomedical Research Ethics
(1994/2920).
Methylation analysis
Recently, we developed a multiplex methylation assay in
order to detect bladder cancer in voided urine [6]. This assay
consisted of probes covering CpG-sites in five different genes,
namely OSR1, OTX1, ONECUT2, MEIS1 and SIM. Methylation
analysis was performed using the EZ DNA Methylation-Gold™
Kit (Zymo Research Corporation, Irvine, California, USA)
according to the manufacturer’s protocol. Briefly, DNA was
treated with sodium bisulfite, followed by bisulfite-specific PCR
for the five regions of interest. For each PCR reaction a DNA
input of 20ng and PCR primer concentration of 20 pM was
required. After the PCR, a Single Nucleotide Primer Extension
(SNuPE) analysis was performed, using primers that annealed
to the PCR product adjacent to the cytosine of interest. SNuPE
probes were extended with a labeled dideoxynucleotide and
the products were analyzed on an automatic sequencer (ABI
PRISM 3100 Genetic Analyzer, Applied Biosystems), with the
label indicating the presence or absence of a methylated
cytosine. See Kandimalla et al for details on the primers and
probes used [6]. For each gene, the methylation percentage
was calculated by dividing the height of the methylated peak by
the sum of the height of the methylated and unmethylated
peaks multiplied by hundred.
Statistical analysis
Statistical analyses were performed using the Statistical
Package for Social Sciences 20 (SPSS, Chicago) and R
statistical Software for Statistical Computing (Vienna).
Univariable and multivariable logistic regression models were
used to calculate the association between UCC and the
predictor variables. The predictive accuracy of the model was
determined by the area under the curve (AUC). The Bootstrap
procedure was used for internal validation of the predictive
model. P-values <0.05 were considered statistically significant.
Results
A total of 169 patients with painless microscopic or
macroscopic hematuria were included in this study, comprising
104 men and 65 women. The mean age was 59 years (range
17-92). Patients and tumor characteristics are depicted in
Table 1. In 54 cases, a bladder tumor was the cause of
hematuria. In the remaining 115 patients, the cause of
hematuria was non-malignant. Patients with UCC were
significantly older and presented more frequent with
macroscopic hematuria compared to patients with a non-
malignant cause(p<0.001 and p=0.002). Cytology was
performed in 81% of the patients. The sensitivity and specificity
for cytology were 39% and 97, retrospectively.
Methylation analysis was performed for OSR1, SIM2, OTX1,
MEIS1 and ONECUT2 and methylation percentages were
calculated. Next, univariable logistic regression analysis was
performed for the methylation percentages of the five different
genes and the clinical variables age, gender, type of hematuria
and cytology (Table 2). OSR1, SIM2, OTX1, MEIS1,
ONECUT2, age, type of hematuria and cytology were all
significant predictors for the presence of UCC. In order to
calculate the combined effect, multivariable logistic regression
analysis was performed. First a model was developed, based
on the methylation percentages of the five genes and the
clinical variables age, gender and type of hematuria. This
resulted in an apparent AUC of 0.88 (Figure 1). In this model
age, type of hematuria, ONECUT2, OSR1 and SIM2 were
independent predictors for the presence of UCC (Table 3).
After internal validation by bootstrapping, the optimism-
corrected AUC was 0.84. To discriminate between patients at
low-risk for UCC vs. patients at high-risk for UCC, a cut-off
value with optimal sensitivity and specificity was determined.
Based on a cut-off of 0.307, 44/54 of patients with UCC were in
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the high-risk group, resulting in a sensitivity of 82%. 94/115
(82%) of patients without a malignancy were in the low-risk
group. In figure 2, the predictive values are shown according to
stage (Figure 2A) and grade (Figure 2B) of the detected
tumors. Tumors that were detected in patients in the low-risk
group were mostly low stage and low grade. However, there
was also one patient with a grade 3 tumor. On the other hand,
all patients with a ≥pT2 tumor were in the high-risk group. In
order to determine the additional value of cytology, a second
model was developed. This model resulted in an AUC of 0.89
as shown in table 3 and an optimism-corrected AUC of 0.85.
Based on a cut-off of 0.306, the sensitivity and specificity for
the second model were 85% (39/46) and 87% (80/92),
respectively.
Discussion
Painless hematuria is a major problem in urological practice
and the distinction between malignant and non-malignant
causes is crucial. In this study, we developed a prediction
model for the assessment of patients presenting with painless
microscopic or macroscopic hematuria. With this newly
developed model, the urologist will be able to adjust patient
examination according to patient risk, resulting in a reduction of
costs and patients discomfort. Previously, the five methylation
markers were proven to be sensitive for the detection of
recurrent UCC [6]. The methylation assay also appeared highly
reproducible between different investigators. In the current
study, the five markers discriminated with a high sensitivity
between patients with and those without primary bladder
Table 1. Clinical and histopathological characteristics of
169 patients presenting with painless hematuria.
   Hematuria UCC+  Hematuria UCC-
   n=54  n=115
Age  Mean (range) 67 (29-92)  55 (17-86)
   n (%)  n (%)
Sex  Male 37 (69)  67 (58)
  Female 17 (31)  48 (42)
Hematuria microscopic 18 (33)  68 (59)
  macroscopic 36 (67)  47 (41)
Cytology no tumor cells 28 (52)  89 (77)
  tumor cells 18 (33)  3 (3)
  not performed 8 (15)  23 (20)
Stage  Ta 30 (55)   
  T1 7 (13)   
  >=T2 13 (24)   
  Tx 3 (6)   
  Tis 1 (2)   
Grade WHO1973 G1 6 (11)   
  G2 11 (20)   
  G3 19 (35)   
  Gx 4 (7,5)   
 WHO2004 Low Grade 10 (19)   
  High Grade 4 (7,5)   
doi: 10.1371/journal.pone.0077657.t001
cancer. Addition of the clinical variables age gender and type of
hematuria increased the accuracy of the model. Age is one of
the greatest risk factors for the development of bladder cancer
and since men have a 3-4 times higher chance of developing
UCC compared to women, gender also contributes significantly
[7]. The use of cytology even more improved the diagnostic
accuracy. Yet, we believe that the use of cytology as diagnostic
test especially for the detection of low grade tumors is
debatable. Therefore, we decided to calculate the fist prediction
model without the addition of cytology. Inclusion of smoking
history may even improve the predictive value further, since
previous studies demonstrated that a history of smoking is an
important independent predictor in the evaluation of hematuria
[7-9]. However, smoking history was unavailable for the
patients in this study.
Table 2. Univariable logistic regression analyses assessing
the association between predictors and the presence of
urothelial cell carcinoma.
 OR 95% CI p value AUC
Age (continuous) 1.062 (1.033, 1.092) <0.001 0.72
Gender 0.641 (0.324, 1.270) 0.203 0.55
Type of hematuria 2.894 (1.033, 1.092) 0,002 0,63
Cytology 19.071 (5.229, 69.555) <0.001 0.68
OTX ratio 1.061 (1.031, 1.093) <0.001 0.69
ONECUT ratio 1.096 (1.050, 1.144) <0.001 0.78
OSR ratio 1.072 (1.041, 1.103) <0.001 0.75
SIM ratio 1.043 (1.021, 1.066) <0.001 0.60
MEIS ratio 1.069 (1.034, 1.105) <0.001 0.71
doi: 10.1371/journal.pone.0077657.t002
Figure 1.  ROC of the multivariable model (AUC 0.88).  
doi: 10.1371/journal.pone.0077657.g001
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Up to now, multiple studies have been performed on the use
of molecular tests in the diagnosis of bladder cancer in patients
presenting with hematuria and some of these assays are
already FDA approved [10-13]. However, due to suboptimal
sensitivities and specificities, the analyses are mostly
performed in addition to cystoscopy. Abogunrin et al.
investigated whether biomarkers were able to improve the
predictive power of a risk model which was based on clinical
variables [14]. They considered the additional predictive value
of nine different biomarkers to the prior predictive probability
(PPP) that was based on age and smoking. They concluded
that the addition of nuclear matrix protein 22 and vascular
Table 3. Multivariable logistic regression analyses
assessing the association between predictors and the
presence of urothelial cell carcinoma.
Multivariable model 1    
 OR 95% CI p value AUC (%)
Age (continuous) 1.047 1.014, 1.081 0.005 88.1
Gender 0.924 0.376, 2.275 0.864  
Type of hematuria 3.743 1.521, 9.212 0.004  
OTX ratio 1.038 0.936, 1.152 0.478  
ONECUT ratio 1.117 1.015, 1.228 0.024  
OSR ratio 1.010 1.010, 1.124 0.020  
SIM ratio 0.829 0.829, 0.980 0.015  
MEIS ratio 0.986 0.919, 1.057 0.686  
Multivariable model 2 (including cytology)   
 OR 95% CI p value AUC (%)
Age (continuous) 1.032 0.997, 1.069 0.077 89.5
Gender 0.693 0.242, 1.989 0.496  
Type of hematuria 2.347 0.866, 6.361 0.094  
Cytology 10.956 2.269, 52.918 0.003  
OTX ratio 1.053 0.938, 1.181 0.384  
ONECUT ratio 1.085 0.981, 1.201 0.113  
OSR ratio 1.080 1.018, 1.145 0.010  
SIM ratio 0.875 0.786, 0.973 0.014  
MEIS ratio 0.988 0.907, 1.076 0.784  
doi: 10.1371/journal.pone.0077657.t003
endothelial growth factor to the PPP improved the diagnostic
accuracy from 0.76 to 0.90. In another study by Cha et al, the
authors also combined molecular tests and clinical features into
a multivariable regression model in order to predict the
likelihood of having bladder cancer. They developed a
nomogram based on the commercially available
immunocytology assay (uCyt/ImmunoCyt), in combination with
conventional cytology and clinical variables, i.e. age, gender,
smoker, hematuria (microscopic vs. macroscopic) [15]. The
AUC of this multivariable model was 0.904. However, cytology
and immunocytology are highly dependent on the skills and
experience of the pathologist [16].
Figure 2.  Scatterplot of risk values for the detection of
urothelial cell carcinoma (UCC) in patients presenting with
painless hematuria.  X-axis depicts stage (A) and grade (B) of
the resected tumors. Y-axis depicts the risk value based on the
developed logistic regression model. Patients with risk value >
0.307 were considered at high-risk for having UCC. Patients
with a risk value < 0.307 were considered at low-risk. Each dot
represents a urine sample.
doi: 10.1371/journal.pone.0077657.g002
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A limitation of the current study was the retrospective design.
Since this was not a consecutive series of patients, the
composition of the patient cohort does not reflect true clinical
practice. In addition, this model was internally validated by
using the bootstrap method [17]. Therefore we suggest this
model should be externally validated in a large prospective
patient cohort of patients presenting with painless microscopic
or macroscopic hematuria.
In conclusion, we developed an accurate risk model for the
evaluation of patients presenting with painless hematuria.
Predicting the risk of bladder cancer in these patients could be
of great value, resulting in less extensive examination of low
risk patients and reduction of costs. Further validation in a large
prospective patient cohort is necessary to prove the true
clinical value of this newly developed model.
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